bplist00Ñ_WebMainResourceÕ
_WebResourceFrameName^WebResourceURL_WebResourceData_WebResourceMIMEType_WebResourceTextEncodingNameP_?file:///Users/christianbopoulsen/Downloads/atc-kode.xls-35.htmlO ñ|
Sundhedsdatastyrelsen - Statistikker
- ATC code: C03AA01, C03AA02, C03AA03, C03AA04, C03AA05, C03AB01, C03AB02, C03BA03, C03BA04, C03BA05, C03BA11, C03BB03, C03CA01, C03CA02, C03CB02, C03DA01, C03DA02, C03DA04, C03DB01, C03EA01, C03EB01, C03EB02, C03XA01
- Search variable: Volume sold
- Age groups: 0 - 4 y.o., 5 - 9 y.o., 10 - 14 y.o., 15 - 19 y.o.
- Gender: Gender, combined
- Sector: Primary sector
- Region: Entire Denmark
- ATC code: C03AA01 (bendroflumethiazide)
|
1999 |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
Share of prescription sales to individuals of total primary sales |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
- |
- |
- |
- |
- |
- |
Prescription sales to individuals |
Volume sold (1,000 DDD) |
0 - 4 y.o. |
2 |
3 |
3 |
1 |
0 |
1 |
0 |
0 |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
5 - 9 y.o. |
0 |
- |
0 |
0 |
2 |
2 |
1 |
2 |
2 |
3 |
2 |
1 |
- |
- |
- |
- |
- |
- |
10 - 14 y.o. |
1 |
0 |
- |
1 |
1 |
3 |
3 |
3 |
2 |
1 |
6 |
2 |
- |
- |
- |
- |
- |
- |
15 - 19 y.o. |
1 |
1 |
1 |
1 |
2 |
2 |
3 |
3 |
3 |
5 |
5 |
5 |
- |
- |
- |
- |
- |
- |
- ATC code: C03AA02 (hydroflumethiazide)
|
1999 |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
Share of prescription sales to individuals of total primary sales |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Prescription sales to individuals |
Volume sold (1,000 DDD) |
0 - 4 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
5 - 9 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
10 - 14 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
15 - 19 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- ATC code: C03AA03 (hydrochlorothiazide)
|
1999 |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
Share of prescription sales to individuals of total primary sales |
99% |
99% |
99% |
99% |
99% |
- |
- |
- |
- |
- |
- |
- |
- |
- |
99% |
98% |
99% |
99% |
Prescription sales to individuals |
Volume sold (1,000 DDD) |
0 - 4 y.o. |
2 |
2 |
2 |
0 |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
0 |
5 - 9 y.o. |
6 |
7 |
3 |
4 |
2 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
0 |
1 |
0 |
10 - 14 y.o. |
1 |
1 |
6 |
8 |
4 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
1 |
2 |
1 |
0 |
15 - 19 y.o. |
- |
1 |
1 |
1 |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
0 |
1 |
2 |
- ATC code: C03AA04 (chlorothiazide)
|
1999 |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
Share of prescription sales to individuals of total primary sales |
>99% |
94% |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Prescription sales to individuals |
Volume sold (1,000 DDD) |
0 - 4 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
5 - 9 y.o. |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
10 - 14 y.o. |
0 |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
15 - 19 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- ATC code: C03AA05 (polythiazide)
|
1999 |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
Share of prescription sales to individuals of total primary sales |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Prescription sales to individuals |
Volume sold (1,000 DDD) |
0 - 4 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
5 - 9 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
10 - 14 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
15 - 19 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- ATC code: C03AB01 (bendroflumethiazide and potassium)
|
1999 |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
Share of prescription sales to individuals of total primary sales |
99% |
99% |
99% |
99% |
99% |
99% |
99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
Prescription sales to individuals |
Volume sold (1,000 DDD) |
0 - 4 y.o. |
1 |
1 |
0 |
- |
0 |
- |
0 |
0 |
0 |
0 |
- |
- |
0 |
0 |
0 |
- |
- |
- |
5 - 9 y.o. |
0 |
0 |
1 |
0 |
1 |
1 |
1 |
0 |
1 |
1 |
0 |
1 |
2 |
1 |
1 |
2 |
1 |
1 |
10 - 14 y.o. |
3 |
2 |
1 |
1 |
3 |
5 |
7 |
5 |
4 |
2 |
3 |
4 |
7 |
7 |
5 |
4 |
4 |
1 |
15 - 19 y.o. |
9 |
9 |
8 |
7 |
11 |
13 |
12 |
11 |
13 |
15 |
12 |
10 |
12 |
11 |
16 |
15 |
14 |
7 |
- ATC code: C03AB02 (hydroflumethiazide and potassium)
|
1999 |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
Share of prescription sales to individuals of total primary sales |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Prescription sales to individuals |
Volume sold (1,000 DDD) |
0 - 4 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
5 - 9 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
10 - 14 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
15 - 19 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- ATC code: C03BA03 (clopamide)
|
1999 |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
Share of prescription sales to individuals of total primary sales |
>99% |
>99% |
>99% |
>99% |
- |
- |
>99% |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Prescription sales to individuals |
Volume sold (1,000 DDD) |
0 - 4 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
5 - 9 y.o. |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
10 - 14 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
15 - 19 y.o. |
- |
- |
- |
- |
- |
- |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- ATC code: C03BA04 (chlortalidone)
|
1999 |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
Share of prescription sales to individuals of total primary sales |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Prescription sales to individuals |
Volume sold (1,000 DDD) |
0 - 4 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
5 - 9 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
10 - 14 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
15 - 19 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- ATC code: C03BA05 (mefruside)
|
1999 |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
Share of prescription sales to individuals of total primary sales |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Prescription sales to individuals |
Volume sold (1,000 DDD) |
0 - 4 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
5 - 9 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
10 - 14 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
15 - 19 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- ATC code: C03BA11 (indapamide)
|
1999 |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
Share of prescription sales to individuals of total primary sales |
>99% |
>99% |
>99% |
>99% |
>99% |
- |
- |
- |
- |
- |
- |
>99% |
>99% |
>99% |
- |
- |
- |
- |
Prescription sales to individuals |
Volume sold (1,000 DDD) |
0 - 4 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
5 - 9 y.o. |
- |
- |
- |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
10 - 14 y.o. |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
15 - 19 y.o. |
0 |
0 |
0 |
0 |
0 |
- |
- |
- |
- |
- |
- |
0 |
0 |
0 |
- |
- |
- |
- |
- ATC code: C03BB03 (clopamide and potassium)
|
1999 |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
Share of prescription sales to individuals of total primary sales |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Prescription sales to individuals |
Volume sold (1,000 DDD) |
0 - 4 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
5 - 9 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
10 - 14 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
15 - 19 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- ATC code: C03CA01 (furosemide)
|
1999 |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
Share of prescription sales to individuals of total primary sales |
>99% |
99% |
99% |
>99% |
99% |
99% |
99% |
99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
Prescription sales to individuals |
Volume sold (1,000 DDD) |
0 - 4 y.o. |
13 |
14 |
15 |
11 |
11 |
13 |
13 |
13 |
11 |
13 |
13 |
11 |
9 |
10 |
7 |
3 |
4 |
4 |
5 - 9 y.o. |
14 |
10 |
9 |
10 |
8 |
7 |
7 |
9 |
9 |
6 |
7 |
7 |
9 |
6 |
8 |
6 |
6 |
5 |
10 - 14 y.o. |
14 |
9 |
14 |
15 |
11 |
13 |
19 |
14 |
13 |
10 |
13 |
10 |
10 |
12 |
11 |
17 |
8 |
12 |
15 - 19 y.o. |
34 |
40 |
37 |
33 |
15 |
23 |
27 |
46 |
32 |
32 |
38 |
27 |
28 |
28 |
28 |
21 |
33 |
42 |
- ATC code: C03CA02 (bumetanide)
|
1999 |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
Share of prescription sales to individuals of total primary sales |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
Prescription sales to individuals |
Volume sold (1,000 DDD) |
0 - 4 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
0 |
- |
- |
- |
0 |
- |
- |
- |
- |
0 |
5 - 9 y.o. |
- |
- |
- |
- |
- |
- |
- |
0 |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
10 - 14 y.o. |
- |
- |
- |
0 |
- |
0 |
- |
- |
- |
- |
2 |
4 |
2 |
1 |
0 |
- |
0 |
- |
15 - 19 y.o. |
0 |
0 |
0 |
0 |
0 |
2 |
4 |
4 |
5 |
4 |
3 |
0 |
0 |
2 |
5 |
2 |
1 |
1 |
- ATC code: C03CB02 (bumetanide and potassium)
|
1999 |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
Share of prescription sales to individuals of total primary sales |
- |
- |
>99% |
>99% |
>99% |
>99% |
- |
- |
>99% |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Prescription sales to individuals |
Volume sold (1,000 DDD) |
0 - 4 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
5 - 9 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
10 - 14 y.o. |
- |
- |
- |
- |
0 |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
15 - 19 y.o. |
- |
- |
0 |
0 |
0 |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- ATC code: C03DA01 (spironolactone)
|
1999 |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
Share of prescription sales to individuals of total primary sales |
>99% |
>99% |
99% |
99% |
>99% |
>99% |
99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
Prescription sales to individuals |
Volume sold (1,000 DDD) |
0 - 4 y.o. |
1 |
1 |
1 |
2 |
2 |
3 |
4 |
3 |
3 |
2 |
1 |
1 |
1 |
1 |
0 |
0 |
0 |
0 |
5 - 9 y.o. |
1 |
1 |
2 |
3 |
2 |
2 |
3 |
3 |
3 |
3 |
3 |
2 |
3 |
3 |
3 |
3 |
2 |
2 |
10 - 14 y.o. |
2 |
1 |
2 |
4 |
5 |
4 |
6 |
5 |
7 |
6 |
6 |
5 |
4 |
5 |
3 |
3 |
5 |
4 |
15 - 19 y.o. |
1 |
3 |
3 |
3 |
5 |
6 |
5 |
7 |
8 |
7 |
9 |
10 |
10 |
12 |
10 |
8 |
8 |
12 |
- ATC code: C03DA02 (potassium canrenoate)
|
1999 |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
Share of prescription sales to individuals of total primary sales |
- |
>99% |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Prescription sales to individuals |
Volume sold (1,000 DDD) |
0 - 4 y.o. |
- |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
5 - 9 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
10 - 14 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
15 - 19 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- ATC code: C03DA04 (eplerenone)
|
1999 |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
Share of prescription sales to individuals of total primary sales |
- |
- |
- |
- |
- |
- |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
Prescription sales to individuals |
Volume sold (1,000 DDD) |
0 - 4 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
5 - 9 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
10 - 14 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
0 |
15 - 19 y.o. |
- |
- |
- |
- |
- |
- |
0 |
0 |
2 |
2 |
1 |
1 |
1 |
1 |
1 |
1 |
0 |
1 |
- ATC code: C03DB01 (amiloride)
|
1999 |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
Share of prescription sales to individuals of total primary sales |
>99% |
99% |
>99% |
99% |
>99% |
>99% |
>99% |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Prescription sales to individuals |
Volume sold (1,000 DDD) |
0 - 4 y.o. |
0 |
0 |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
5 - 9 y.o. |
3 |
3 |
2 |
2 |
2 |
1 |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
10 - 14 y.o. |
0 |
1 |
3 |
3 |
3 |
3 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
15 - 19 y.o. |
1 |
1 |
1 |
0 |
0 |
1 |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- ATC code: C03EA01 (hydrochlorothiazide and potassium-sparing agents)
|
1999 |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
Share of prescription sales to individuals of total primary sales |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
>99% |
Prescription sales to individuals |
Volume sold (1,000 DDD2) |
0 - 4 y.o. |
- |
- |
- |
- |
2 |
3 |
1 |
- |
- |
0 |
- |
- |
- |
- |
- |
- |
- |
0 |
5 - 9 y.o. |
- |
0 |
- |
0 |
1 |
1 |
3 |
4 |
2 |
2 |
2 |
- |
- |
1 |
2 |
3 |
3 |
3 |
10 - 14 y.o. |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
3 |
4 |
3 |
4 |
3 |
2 |
3 |
2 |
1 |
1 |
15 - 19 y.o. |
2 |
1 |
0 |
1 |
0 |
0 |
1 |
2 |
6 |
6 |
6 |
5 |
3 |
4 |
5 |
2 |
4 |
5 |
- ATC code: C03EB01 (furosemide and potassium-sparing agents)
|
1999 |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
Share of prescription sales to individuals of total primary sales |
- |
>99% |
- |
>99% |
- |
- |
- |
- |
- |
- |
>99% |
>99% |
- |
- |
- |
- |
- |
>99% |
Prescription sales to individuals |
Volume sold (1,000 DDD2) |
0 - 4 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
5 - 9 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
10 - 14 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
0 |
0 |
- |
- |
- |
- |
- |
0 |
15 - 19 y.o. |
- |
0 |
- |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- ATC code: C03EB02 (bumetanide and potassium-sparing agents)
|
1999 |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
Share of prescription sales to individuals of total primary sales |
>99% |
>99% |
- |
- |
>99% |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Prescription sales to individuals |
Volume sold (1,000 DDD2) |
0 - 4 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
5 - 9 y.o. |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
10 - 14 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
15 - 19 y.o. |
- |
0 |
- |
- |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- ATC code: C03XA01 (tolvaptan)
|
1999 |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
Share of prescription sales to individuals of total primary sales |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Prescription sales to individuals |
Volume sold (1,000 DDD) |
0 - 4 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
5 - 9 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
10 - 14 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
15 - 19 y.o. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- Legend
- 0 or 0.0 The value is so small that it can not be displayed after rounding.
- - No sale, no data or not calculated.
- Notes
- 2 : Some medicines are Combination Products. This has implications for the DDD value.
Ytext/htmlUUTF-8 ( ? N ` v ” • × òY òc
òi